Health Care • Medical/Dental Instruments
$0.54 ▲ +0.01
(+1.34%)
MKT CAP: $30.4M • VOL: 2.48M
52W L $0 52W H $4
ROARABLE / RQD
D • 50/100
PIOTROSKI
2 / 9
BEAT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$21.1M | -$19.9M | -$15.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$21.0M | -$19.4M | -$14.6M |
| EBITDA (Normalized) | -$20.7M | -$19.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$14.0M | -$14.5M | -$12.1M |
| Capital Expenditures (CapEx) | $600.0K | $201.0K | — |
| Free Cash Flow (FCF) | -$14.6M | -$14.7M | -$12.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.4M | $2.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $2.6M | $1.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BEAT.